| Year |
Citation |
Score |
| 2020 |
Arranz MJ, Salazar J, Hernández MH. Pharmacogenetics of antipsychotics: Clinical utility and implementation. Behavioural Brain Research. 113058. PMID 33316324 DOI: 10.1016/j.bbr.2020.113058 |
0.359 |
|
| 2016 |
Catalán R, González-Rodríguez A, Arranz M, Penadés R, Gutiérrez B, Pérez-Blanco F, Bernardo M. Impact of nicotine consumption on antipsychotic response based on genetic variants of cytochrome P450 2D6 and multi-drug resistance 1 C3435T in schizophrenia European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31599-1 |
0.41 |
|
| 2015 |
Mitjans M, Catalán R, Vázquez M, González-Rodríguez A, Penadés R, Pons A, Massana G, Munro J, Arranz MJ, Arias B. Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response: association with FKBP5 and NTRK2 genes. Pharmacogenetics and Genomics. 25: 274-7. PMID 25751398 DOI: 10.1097/FPC.0000000000000132 |
0.397 |
|
| 2014 |
Bramon E, Pirinen M, Strange A, Lin K, Freeman C, Bellenguez C, Su Z, Band G, Pearson R, Vukcevic D, Langford C, Deloukas P, Hunt S, ... ... Arranz MJ, et al. A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biological Psychiatry. 75: 386-97. PMID 23871474 DOI: 10.1016/J.Biopsych.2013.03.033 |
0.387 |
|
| 2013 |
Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, Kim Y, Lee SH, Magnusson PK, Sanchez N, Stahl EA, ... ... Arranz MJ, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics. 45: 1150-9. PMID 23974872 DOI: 10.1038/Ng.2742 |
0.332 |
|
| 2013 |
Shaikh M, Hall MH, Schulze K, Dutt A, Li K, Williams I, Walshe M, Constante M, Broome M, Picchioni M, Toulopoulou T, Collier D, Stahl D, Rijsdijk F, Powell J, ... ... Arranz M, et al. Effect of DISC1 on the P300 waveform in psychosis. Schizophrenia Bulletin. 39: 161-7. PMID 21878470 DOI: 10.1093/Schbul/Sbr101 |
0.459 |
|
| 2012 |
Prata DP, Gafoor R, Kay V, Arranz M, Munro J, McGuire P. Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis. Journal of Clinical Psychopharmacology. 32: 566-9. PMID 22760349 DOI: 10.1097/Jcp.0B013E31825Ec2Cb |
0.432 |
|
| 2012 |
Munro J, Skrobot O, Sanyoura M, Kay V, Susce MT, Glaser PE, de Leon J, Blakemore AI, Arranz MJ. Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. Journal of Psychopharmacology (Oxford, England). 26: 374-9. PMID 21693553 DOI: 10.1177/0269881111408965 |
0.314 |
|
| 2011 |
Arranz MJ, Munro JC. Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. Expert Review of Clinical Pharmacology. 4: 389-405. PMID 22114782 DOI: 10.1586/ecp.11.16 |
0.344 |
|
| 2011 |
Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. Cns Drugs. 25: 933-69. PMID 22054119 DOI: 10.2165/11595380-000000000-00000 |
0.495 |
|
| 2011 |
Ivorra JL, D'Souza UM, Jover M, Arranz MJ, Williams BP, Henry SE, Sanjuan J, Molto MD. Association between neonatal temperament, SLC6A4, DRD4 and a functional polymorphism located in TFAP2B. Genes, Brain, and Behavior. 10: 570-8. PMID 21504541 DOI: 10.1111/J.1601-183X.2011.00696.X |
0.435 |
|
| 2011 |
Dutt A, Shaikh M, Ganguly T, Nosarti C, Walshe M, Arranz M, Rifkin L, McDonald C, Chaddock CA, McGuire P, Murray RM, Bramon E, Allin MP. COMT gene polymorphism and corpus callosum morphometry in preterm born adults. Neuroimage. 54: 148-53. PMID 20659569 DOI: 10.1016/J.Neuroimage.2010.07.048 |
0.405 |
|
| 2011 |
Shaikh M, Hall MH, Schulze K, Dutt A, Walshe M, Williams I, Constante M, Picchioni M, Toulopoulou T, Collier D, Rijsdijk F, Powell J, Arranz M, Murray RM, Bramon E. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis? Psychological Medicine. 41: 263-76. PMID 20102668 DOI: 10.1017/S003329170999239X |
0.42 |
|
| 2011 |
Shaikh M, Hall M, Schulze K, Dutt A, Walshe M, Williams I, Constante M, Picchioni M, Touloupolou T, Rijsdijk F, Powell J, Arranz M, Murray R, Bramon E. Do COMT, BDNF and NRG-1 polymorphisms influence P50 sensory gating in psychosis? International Clinical Psychopharmacology. 26: e112-e113. DOI: 10.1097/01.Yic.0000405823.32432.50 |
0.37 |
|
| 2010 |
Perez-Iglesias R, Mata I, Amado JA, Berja A, Garcia-Unzueta MT, MartÃnez GarcÃa O, Arranz MJ, Vazquez-Barquero JL, Crespo-Facorro B. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. Journal of Clinical Psychopharmacology. 30: 661-6. PMID 21105276 DOI: 10.1097/JCP.0b013e3181fae248 |
0.348 |
|
| 2010 |
Vázquez-Bourgon J, Arranz MJ, Mata I, Pelayo-Terán JM, Pérez-Iglesias R, Medina-González L, Carrasco-MarÃn E, Vázquez-Barquero JL, Crespo-Facorro B. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Research. 175: 189-94. PMID 20031235 DOI: 10.1016/j.psychres.2008.12.011 |
0.45 |
|
| 2010 |
Hwang R, Zai C, Tiwari A, Müller DJ, Arranz MJ, Morris AG, McKenna PJ, Munro J, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. The Pharmacogenomics Journal. 10: 200-18. PMID 20029384 DOI: 10.1038/Tpj.2009.65 |
0.359 |
|
| 2010 |
Shaikh M, Hall M, Schulze K, Dutt A, Walshe M, Williams I, Constante M, Picchione M, Toulopoulou T, Collier D, Rijsdijk F, Powell J, Arranz M, Murray R, Bramon-Bosch E. No Association Between Comt, Bdnf And Nrg-1 Polymorphisms And P50 Sensory Gating In Psychosis Schizophrenia Research. 117: 484-485. DOI: 10.1016/J.Schres.2010.02.917 |
0.384 |
|
| 2009 |
Diaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, de Leon J. Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophrenia Research. 115: 136-40. PMID 19846279 DOI: 10.1016/j.schres.2009.09.038 |
0.303 |
|
| 2009 |
Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glaser PE, Clark D, de Leon J. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatric Genetics. 19: 305-11. PMID 19829168 DOI: 10.1097/YPG.0b013e3283328dcd |
0.363 |
|
| 2009 |
Clark D, Skrobot OA, Adebiyi I, Susce MT, de Leon J, Blakemore AF, Arranz MJ. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. European Psychiatry : the Journal of the Association of European Psychiatrists. 24: 456-63. PMID 19541455 DOI: 10.1016/J.Eurpsy.2009.03.003 |
0.427 |
|
| 2008 |
Pelayo-Terán JM, Crespo-Facorro B, Carrasco-MarÃn E, Pérez-Iglesias R, Mata I, Arranz MJ, Leyva-Cobián F, Vázquez-Barquero JL. Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 550-6. PMID 18092319 DOI: 10.1002/ajmg.b.30639 |
0.393 |
|
| 2008 |
de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia Research. 98: 40-6. PMID 18031993 DOI: 10.1016/j.schres.2007.10.003 |
0.33 |
|
| 2008 |
Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ, de Leon J. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Human Psychopharmacology. 23: 107-14. PMID 17972277 DOI: 10.1002/Hup.903 |
0.553 |
|
| 2007 |
Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry. 12: 707-47. PMID 17549063 DOI: 10.1038/Sj.Mp.4002009 |
0.517 |
|
| 2007 |
Mancama D, Mata I, Kerwin RW, Arranz MJ. Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 144: 849-53. PMID 17503482 DOI: 10.1002/Ajmg.B.30468 |
0.55 |
|
| 2007 |
Parsons MJ, Mata I, Beperet M, Iribarren-Iriso F, Arroyo B, Sainz R, Arranz MJ, Kerwin R. A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatric Genetics. 17: 159-63. PMID 17417059 DOI: 10.1097/Ypg.0B013E328017F8A4 |
0.617 |
|
| 2007 |
Clark DA, Mata I, Kerwin RW, Munro J, Arranz MJ. No association between ADRA2A polymorphisms and schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 144: 341-3. PMID 17034020 DOI: 10.1002/Ajmg.B.30355 |
0.618 |
|
| 2006 |
Mata I, Crespo-Facorro B, Pérez-Iglesias R, Carrasco-MarÃn E, Arranz MJ, Pelayo-Terán JM, Leyva-CobÃan F, Vázquez-Barquero JL. Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 141: 939-43. PMID 16921503 DOI: 10.1002/ajmg.b.30405 |
0.342 |
|
| 2006 |
Clark DA, Mancama D, Kerwin RW, Arranz MJ. Expression of the alpha1A-adrenergic receptor in schizophrenia. Neuroscience Letters. 401: 248-51. PMID 16600500 DOI: 10.1016/J.Neulet.2006.03.025 |
0.581 |
|
| 2005 |
Clark DA, Arranz MJ, Mata I, Lopéz-Ilundain J, Pérez-Nievas F, Kerwin RW. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biological Psychiatry. 58: 435-9. PMID 16043131 DOI: 10.1016/J.Biopsych.2005.04.051 |
0.62 |
|
| 2005 |
Staddon S, Arranz MJ, Mancama D, Perez-Nievas F, Arrizabalaga I, Anney R, Buckland P, Elkin A, Osborne S, Munro J, Mata I, Kerwin RW. Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. Schizophrenia Research. 73: 49-54. PMID 15567076 DOI: 10.1016/J.Schres.2004.06.011 |
0.634 |
|
| 2004 |
Bolonna AA, Arranz MJ, Mancama D, Kerwin RW. Pharmacogenomics--can genetics help in the care of psychiatric patients? International Review of Psychiatry (Abingdon, England). 16: 311-9. PMID 16194764 DOI: 10.1080/09540260400014369 |
0.61 |
|
| 2004 |
Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biological Psychiatry. 56: 406-10. PMID 15364038 DOI: 10.1016/J.Biopsych.2004.06.020 |
0.531 |
|
| 2004 |
Huezo-Diaz P, Arranz MJ, Munro J, Osborne S, Makoff A, Kerwin RW, Austin J, O'Donovan M. An association study of the neurotensin receptor gene with schizophrenia and clozapine response. Schizophrenia Research. 66: 193-5. PMID 15061255 DOI: 10.1016/S0920-9964(03)00128-2 |
0.657 |
|
| 2004 |
Mata I, Arranz MJ, Patiño A, Lai T, Beperet M, Sierrasesumaga L, Clark D, Perez-Nievas F, Richards L, Ortuño F, Sham P, Kerwin RW. Serotonergic polymorphisms and psychotic disorders in populations from North Spain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 126: 88-94. PMID 15048655 DOI: 10.1002/Ajmg.B.20150 |
0.625 |
|
| 2004 |
Mancama D, Arranz M, Staddon S, Parsons M, Clark D, Osborne S, Munro J, Kerwin R. S.4.07 Applications of pharmacogenetics and pharmacogenomics in the improvement of psychiatric treatment European Neuropsychopharmacology. 14: S68. DOI: 10.1016/S0924-977X(04)90085-5 |
0.478 |
|
| 2004 |
Clark D, Staddon S, Mata I, Mancama D, Arranz M, Kerwin R. S.4.02 Dopamine 3 (D3) receptors genetic variants: influence in schizophrenia and antipsychotic response European Neuropsychopharmacology. 14: S64-S65. DOI: 10.1016/S0924-977X(04)90080-6 |
0.628 |
|
| 2004 |
Parsons M, Mancama D, Arranz M, Kerwin R. P.1.07 Gene expression profiling to identify new targets associated with schizophrenia and its treatment European Neuropsychopharmacology. 14: S7-S8. DOI: 10.1016/S0924-977X(04)90008-9 |
0.585 |
|
| 2003 |
Mancama D, Arranz MJ, Kerwin RW. Pharmacogenomics of psychiatric drug treatment. Current Opinion in Molecular Therapeutics. 5: 642-9. PMID 14755891 |
0.511 |
|
| 2003 |
Arranz MJ, Kerwin RW. Advances in the pharmacogenetic prediction of antipsychotic response. Toxicology. 192: 33-5. PMID 14511901 DOI: 10.1016/S0300-483X(03)00248-8 |
0.598 |
|
| 2003 |
Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 119: 40-3. PMID 12707936 DOI: 10.1002/Ajmg.B.10068 |
0.386 |
|
| 2003 |
Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 119: 2-6. PMID 12707929 DOI: 10.1002/Ajmg.B.20020 |
0.624 |
|
| 2003 |
Mundo E, Tharmalingham S, Neves-Pereira M, Dalton EJ, Macciardi F, Parikh SV, Bolonna A, Kerwin RW, Arranz MJ, Makoff AJ, Kennedy JL. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Molecular Psychiatry. 8: 241-5. PMID 12610658 DOI: 10.1038/Sj.Mp.4001218 |
0.568 |
|
| 2003 |
Staddon S, Arranz M, Buckland P, Osborne S, Mata I, Kerwin R. Polymorphisms in the dopamine D3 receptor gene and improvement in positive symptoms of schizophrenia Schizophrenia Research. 60: 90-91. DOI: 10.1016/S0920-9964(03)80656-4 |
0.624 |
|
| 2003 |
Mancama DT, Mata I, Munro J, Osborne S, Arranz M, Kerwin R. Analysis of muscarinic 1 promoter polymorphisms on receptor expression and outcome to atypical antipsychotic treatment Schizophrenia Research. 60: 85-85. DOI: 10.1016/S0920-9964(03)80639-4 |
0.596 |
|
| 2003 |
Clark D, Eva R, Mata I, Arranz M, Kerwin R. Association analysis of polymorphism (ARG492CYS) in the α1A-adrenergic receptor gene with schizophrenia and antipsychotic treatment Schizophrenia Research. 60: 79-80. DOI: 10.1016/S0920-9964(03)80622-9 |
0.677 |
|
| 2003 |
Arranz M, Clark D, Mancama D, Parsons M, Staddon S, Beperet M, Arrondo J, Mata I, Kerwin R. Clinical applications of pharmacogenetics: Pre-treatment prediction of antipsychotic response Schizophrenia Research. 60: 77. DOI: 10.1016/S0920-9964(03)80615-1 |
0.524 |
|
| 2003 |
Mancama D, Arranz MJ, Kerwin RW. Genetic perspectives of histamine and muscarinic receptors in schizophrenia and clozapine response Drug Development Research. 60: 119-126. DOI: 10.1002/Ddr.10291 |
0.591 |
|
| 2003 |
Arranz MJ, Kerwin RW. Pharmacogenetic and pharmacogenomic research for the prediction of response to antipsychotics in schizophrenia Drug Development Research. 60: 104-110. DOI: 10.1002/Ddr.10289 |
0.629 |
|
| 2002 |
Mancama D, Arranz MJ, Munro J, Osborne S, Makoff A, Collier D, Kerwin R. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neuroscience Letters. 333: 207-11. PMID 12429384 DOI: 10.1016/S0304-3940(02)00178-7 |
0.626 |
|
| 2002 |
Arias B, Arranz MJ, Gasto C, Catalan R, Pintor L, Gutierrez B, Kerwin RW, Fananas L. Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. Molecular Psychiatry. 7: 930-2. PMID 12399944 DOI: 10.1038/Sj.Mp.4001146 |
0.564 |
|
| 2002 |
Gutiérrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthiasson P, Travis M, Munro J, Osborne S, Kerwin RW. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophrenia Research. 58: 93-7. PMID 12363396 DOI: 10.1016/S0920-9964(02)00205-0 |
0.613 |
|
| 2002 |
Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology. 162: 18-23. PMID 12107612 DOI: 10.1007/S00213-002-1084-4 |
0.527 |
|
| 2002 |
Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. Cns Drugs. 16: 317-24. PMID 11994021 DOI: 10.2165/00023210-200216050-00004 |
0.556 |
|
| 2001 |
Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 1: 3-10. PMID 12173312 DOI: 10.2165/00129785-200101010-00001 |
0.551 |
|
| 2001 |
Kerwin RW, Mancama DT, Arranz MJ. Genetic strategies for the personalization of antipsychotic treatment. Expert Review of Molecular Diagnostics. 1: 275-80. PMID 11901832 DOI: 10.1586/14737159.1.3.275 |
0.568 |
|
| 2001 |
Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, Lovestone S. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. Journal of Neurology, Neurosurgery, and Psychiatry. 71: 777-9. PMID 11723200 DOI: 10.1136/Jnnp.71.6.777 |
0.483 |
|
| 2001 |
Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opinion On Pharmacotherapy. 2: 537-42. PMID 11336604 DOI: 10.1517/14656566.2.4.537 |
0.578 |
|
| 2001 |
Bolonna AA, Kerwin RW, Munro J, Arranz MJ, Makoff AJ. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophrenia Research. 47: 99-103. PMID 11163549 DOI: 10.1016/S0920-9964(99)00235-2 |
0.581 |
|
| 2001 |
Mata I, Madoz V, Arranz MJ, Sham P, Murray RM. Olanzapine: concordant response in monozygotic twins with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 178: 86. PMID 11136224 DOI: 10.1192/bjp.178.1.86 |
0.306 |
|
| 2001 |
Arranz MJ, Mancama D, Kerwin RW. Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)). International Journal of Molecular Medicine. 7: 27-30. PMID 11115604 DOI: 10.3892/Ijmm.7.1.27 |
0.538 |
|
| 2001 |
Staddon SL, Mata I, Osborne S, Munro J, Huezo-Diaz P, Arranz MJ, Kerwin RW. An association study of the 5-HT6 267-C/T polymorphism and antipsychotic response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 619. |
0.512 |
|
| 2001 |
Mancama DT, Preece P, Landau S, Arranz MJ, Kerwin RW. Relative quantification analysis of cortical histamine 1 and muscarinic 1 receptor expression in patients with schizophrenia American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 623. |
0.537 |
|
| 2001 |
Staddon LS, Mata I Osborne S, Munro J, Huezo-Diaz P, Arranz MJ, Kerwin RW. An association study of the 5-HT6 267-C/T variant and antipsychotic response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 641-642. |
0.479 |
|
| 2001 |
Staddon SL, Arranz MJ, Mata I, Mathiasson P, Richards L, Arroyo B, Kerwin RW. An association study of a D3 polymorphism and olanzapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 641. |
0.522 |
|
| 2001 |
Lai T, Arranz MJ, Mata I, Beperet M, Collier D, Matthiasson P, Kerwin RW. Investigation of 5-HT2C polymorphisms and their influence on olanzapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 641. |
0.558 |
|
| 2001 |
Dempster D, Mancama D, Gutierrez B, Mata I, Beperet M, Arranz MJ, Kerwin RW. An association study of 5-HT5A and 5-HT3B polymorphisms and olanzapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 641. |
0.57 |
|
| 2001 |
Arranz MJ, Staddon S, Mata I, Beperet M, Munro J, Osborne S, Kerwin RW. Genetic predictors of olanzapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 581. |
0.476 |
|
| 2001 |
Mundo E, Tharmalingham S, Dalton J, Bolonna A, Arranz MJ, Kerwin RW, Kennedy JL. The N-Methyl-D-Aspartate receptor subunit 1 gene (GRIN1) and rapid cycling course in Bipolar Disorder American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 621. |
0.476 |
|
| 2001 |
Parsons MJ, D'Souza U, Makoff A, Arranz MJ, Kerwin R. Effects of the -1438-A/G serotonin 2A receptor promotor polymorphism on expression American Journal of Medical Genetics - Neuropsychiatric Genetics. 105: 584. |
0.511 |
|
| 2000 |
Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Difficulties in replication of results. Lancet. 356: 1359-60. PMID 11073057 DOI: 10.1016/S0140-6736(05)74275-6 |
0.412 |
|
| 2000 |
Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport. 11: 2017-20. PMID 10884063 DOI: 10.1097/00001756-200006260-00042 |
0.632 |
|
| 2000 |
Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW. The serotonin transporter and clozapine response. Molecular Psychiatry. 5: 124-5. PMID 10822334 DOI: 10.1038/Sj.Mp.4000652 |
0.432 |
|
| 2000 |
Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW. Pharmacogenetic prediction of clozapine response. Lancet. 355: 1615-6. PMID 10821369 DOI: 10.1016/S0140-6736(00)02221-2 |
0.705 |
|
| 2000 |
Arranz MJ, Kerwin RW. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Annals of Medicine. 32: 128-33. PMID 10766404 DOI: 10.3109/07853890009011762 |
0.579 |
|
| 2000 |
Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, Shaikh S, Grünewald RA. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics. 10: 43-8. PMID 10739171 DOI: 10.1097/00008571-200002000-00006 |
0.638 |
|
| 2000 |
Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, Kerwin RW. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neuroscience Letters. 280: 65-8. PMID 10696813 DOI: 10.1016/S0304-3940(99)01000-9 |
0.642 |
|
| 2000 |
Mancama D, Arranz M, Munro J, Makoff A, Kerwin R. The histamine 1 and histamine 2 receptor genes - candidates for schizophrenia and clozapine drug response Genescreen. 1: 29-34. DOI: 10.1046/J.1466-9218.2000.00005.X |
0.682 |
|
| 2000 |
Mancama D, Munro J, Arranz M, Makoff A, Kerwin R. Novel polymorphisms in the histamine 1 and 2 receptor genes, schizophrenia and clozapine drug response Schizophrenia Research. 41: 242. DOI: 10.1016/S0920-9964(00)90909-5 |
0.68 |
|
| 2000 |
Arranz M, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch K, Meyer J, Sham P, Collier D, Murray R, Kerwin R. Individualisation of treatment: Genetic prediction of clozapine response Schizophrenia Research. 41: 97. DOI: 10.1016/S0920-9964(00)90535-8 |
0.659 |
|
| 2000 |
Arranz MJ, Munro J, Osborne S, Gutierrez B, Huezo P, Dempster D, Hassan BA, Niesler B, Rappold G, Kerwin RW. Novel polymorphisms in 5-HT3A receptor gene not related to schizophrenia and clozapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 96: 538. |
0.643 |
|
| 2000 |
Huezo P, Arranz MJ, Munro J, Osborne S, Austin J, O'Donovan MC, Kerwin RW. Association studies of two neurotensin receptor gene polymorphisms with schizophrenia and clozapine response American Journal of Medical Genetics - Neuropsychiatric Genetics. 96: 539. |
0.649 |
|
| 2000 |
Arranz MJ, Mancama D, Munro J, Osborne S, Travis M, Matthiasson P, Madoz V, Perez-Nievas F, Mata I, Kerwin RW. Influence of polymorphisms in serotonin receptors on response to atypical antipsychotics American Journal of Medical Genetics - Neuropsychiatric Genetics. 96: 466-467. |
0.619 |
|
| 2000 |
Mancama D, Munro J, Arranz MJ, Makoff A, Kerwin R. Association analysis of muscarinic acetylcholine receptor polymorphisms in clozapine treated schizophrenics American Journal of Medical Genetics - Neuropsychiatric Genetics. 96: 540. |
0.392 |
|
| 2000 |
Basile VS, Masellis M, Ozdemir V, Quiterio S, Meltzer HY, Lieberman JA, Mancama D, Arranz MJ, Kerwin RW, Kennedy JL. Novel histamine H1 gene polymorphism and clozapine-induced weight gain American Journal of Medical Genetics - Neuropsychiatric Genetics. 96: 538-539. |
0.477 |
|
| 1999 |
Li T, Liu X, Sham PC, Aitchison KJ, Cai G, Arranz MJ, Deng H, Liu J, Kirov G, Murray RM, Collier DA. Association analysis between dopamine receptor genes and bipolar affective disorder. Psychiatry Research. 86: 193-201. PMID 10482338 DOI: 10.1016/S0165-1781(99)00034-7 |
0.595 |
|
| 1999 |
Breen G, Brown J, Maude S, Fox H, Collier D, Li T, Arranz M, Shaw D, StClair D. -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. American Journal of Medical Genetics. 88: 407-10. PMID 10402509 DOI: 10.1002/(Sici)1096-8628(19990820)88:4<407::Aid-Ajmg19>3.0.Co;2-3 |
0.536 |
|
| 1998 |
Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, Kerwin RW. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 8: 481-4. PMID 9918131 DOI: 10.1097/00008571-199812000-00004 |
0.648 |
|
| 1998 |
Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research. 32: 93-9. PMID 9713904 DOI: 10.1016/S0920-9964(98)00032-2 |
0.623 |
|
| 1998 |
Li T, Arranz M, Aitchison KJ, Bryant C, Liu X, Kerwin RW, Murray R, Sham P, Collier DA. Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophrenia Research. 32: 87-92. PMID 9713903 DOI: 10.1016/S0920-9964(98)00024-3 |
0.723 |
|
| 1998 |
Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Human Molecular Genetics. 7: 1507-9. PMID 9700207 DOI: 10.1093/Hmg/7.9.1507 |
0.304 |
|
| 1998 |
Gutiérrez B, Arranz MJ, Collier DA, Vallès V, Guillamat R, Bertranpetit J, Murray RM, Fãnás L. Serotonin transporter gene and risk for bipolar affective disorder: an association study in Spanish population. Biological Psychiatry. 43: 843-7. PMID 9611675 |
0.318 |
|
| 1998 |
Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kerwin RW. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Molecular Psychiatry. 3: 61-6. PMID 9491814 DOI: 10.1038/Sj.Mp.4000348 |
0.546 |
|
| 1998 |
Mancama D, Munro J, Arranz MJ, Makoff A, Kerwin R. The histaminergic system in schizophrenia and drug response American Journal of Medical Genetics - Neuropsychiatric Genetics. 81: 527-528. |
0.308 |
|
| 1998 |
Arranz MJ, Munro J, Bolonna A, Collier D, Murray R, Kerwin R. Genetic variation in alpha-2A adrenergic receptors and schizophrenia American Journal of Medical Genetics - Neuropsychiatric Genetics. 81: 510. |
0.303 |
|
| 1997 |
Li T, Vallada H, Curtis D, Arranz M, Xu K, Cai G, Deng H, Liu J, Murray R, Liu X, Collier DA. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 7: 349-53. PMID 9352569 DOI: 10.1097/00008571-199710000-00002 |
0.425 |
|
| 1997 |
Gutiérrez B, Bertranpetit J, Collier D, Arranz MJ, Vallès V, Guillamat R, Van Os J, Fañanás L. Genetic variation of the 5-HT2A receptor gene and bipolar affective disorder. Human Genetics. 100: 582-4. PMID 9341875 |
0.335 |
|
| 1997 |
Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, McGuffin P, Owen M, Gill M, Collier DA. Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatric Genetics. 7: 97-101. PMID 9323320 DOI: 10.1097/00041444-199723000-00001 |
0.407 |
|
| 1997 |
Kunugi H, Vallada HP, Hoda F, Kirov G, Gill M, Aitchison KJ, Ball D, Arranz MJ, Murray RM, Collier DA. No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biological Psychiatry. 42: 282-5. PMID 9270905 DOI: 10.1016/S0006-3223(96)00366-6 |
0.541 |
|
| 1997 |
Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet. 350: 412. PMID 9259661 DOI: 10.1016/S0140-6736(05)64135-9 |
0.323 |
|
| 1997 |
Arranz MJ, Erdmann J, Kirov G, Rietschel M, Sodhi M, Albus M, Ball D, Maier W, Davies N, Franzek E, Abusaad I, Weigelt B, Murray R, Shimron-Abarbanell D, Kerwin R, et al. 5-HT2A receptor and bipolar affective disorder: association studies in affected patients. Neuroscience Letters. 224: 95-8. PMID 9086465 DOI: 10.1016/S0304-3940(97)13456-5 |
0.711 |
|
| 1997 |
Gutiérrez B, Bertranpetit J, Guillamat R, Vallès V, Arranz MJ, Kerwin R, Fañanás L. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. The American Journal of Psychiatry. 154: 113-5. PMID 8988970 DOI: 10.1176/Ajp.154.1.113 |
0.516 |
|
| 1997 |
Sodhi MS, Kirov G, Aitchison KJ, Arranz MJ, Collier DA, Kerwin RW. Allelic variation of the 5-HT2C receptor in psychosis Schizophrenia Research. 24: 90-91. DOI: 10.1016/S0920-9964(97)82246-3 |
0.678 |
|
| 1997 |
Birkett JT, Collier DA, Munro J, Arranz MJ, Roberts GW, Price J, Kerwin RW. No association between a novel polymorphism in the 5-HT4 receptor gene and response to clozapine Schizophrenia Research. 24: 90. DOI: 10.1016/S0920-9964(97)82245-1 |
0.574 |
|
| 1996 |
Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Müller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Molecular Psychiatry. 1: 453-60. PMID 9154246 |
0.326 |
|
| 1996 |
Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR, Collier DA. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochemical and Biophysical Research Communications. 228: 780-4. PMID 8941353 DOI: 10.1006/Bbrc.1996.1731 |
0.601 |
|
| 1996 |
Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, Roberts G, Price J, Kerwin RW. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuroscience Letters. 217: 177-8. PMID 8916101 DOI: 10.1016/0304-3940(96)13094-9 |
0.721 |
|
| 1996 |
Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, Aitchison KJ, Sodhi M, Li T, Roberts GW, Smith B, Morton J, Murray RM, Smith D, Kirov G. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport. 7: 1675-9. PMID 8904780 DOI: 10.1097/00001756-199607080-00030 |
0.681 |
|
| 1996 |
Gutiérrez B, Fañanás L, Arranz MJ, Vallès V, Guillamat R, van Os J, Collier D. Allelic association analysis of the 5-HT2C receptor gene in bipolar affective disorder. Neuroscience Letters. 212: 65-7. PMID 8823764 |
0.315 |
|
| 1996 |
Arranz MJ, Lin MW, Powell J, Kerwin R, Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347: 1831-2. PMID 8667939 |
0.348 |
|
| 1996 |
Kerwin R, Collier D, Shaikh S, Arranz M. Pharmacological genetic association studies and clozapine response European Neuropsychopharmacology. 6: 25. DOI: 10.1016/0924-977X(96)87412-8 |
0.572 |
|
| 1996 |
Kunugi H, Vallada HP, Curtis D, Arranz M, Nanko S, Murray RM, Owen M, McGuffin P, Gill M, Collier DA. A transmission disequilibrium study on Catechol-O-Methyltransferase polymorphism in schizophrenia families Schizophrenia Research. 18: 165. DOI: 10.1016/0920-9964(96)85526-5 |
0.398 |
|
| 1996 |
Sodhi M, Kirov G, Arranz M, Ball D, Aitchison K, Kerwin R, Collier D. Association between psychoses and allelic variation in the 5-HT2C receptor gene Schizophrenia Research. 18: 164. DOI: 10.1016/0920-9964(96)85524-1 |
0.697 |
|
| 1995 |
Lin MW, Curtis D, Williams N, Arranz M, Nanko S, Collier D, McGuffin P, Murray R, Owen M, Gill M. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1-q32. Psychiatric Genetics. 5: 117-26. PMID 8746410 DOI: 10.1097/00041444-199505030-00004 |
0.37 |
|
| 1995 |
Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 7: 169-72. PMID 8742444 DOI: 10.1097/00001756-199512000-00041 |
0.749 |
|
| 1995 |
Arranz M, Sharma T, Sham P, Kerwin R, Nanko S, Owen M, Gill M, Collier D. Schizophrenia and the androgen receptor gene: report of a sibship showing co-segregation with Reifenstein syndrome but no evidence for linkage in 23 multiply affected families. American Journal of Medical Genetics. 60: 377-81. PMID 8546149 DOI: 10.1002/Ajmg.1320600506 |
0.609 |
|
| 1995 |
Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K, Crocq MA, Gill M, Kerwin R, Collier DA. Cytochrome P4502D6 genotype does not determine response to clozapine. British Journal of Clinical Pharmacology. 39: 417-20. PMID 7640149 DOI: 10.1111/J.1365-2125.1995.Tb04471.X |
0.697 |
|
| 1995 |
Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 346: 281-2. PMID 7630250 DOI: 10.1016/S0140-6736(95)92168-0 |
0.74 |
|
| 1995 |
Gutiérrez B, Arranz M, Fañanás L, Vallès V, Guillamat R, van Os J, Collier D. 5HT2A receptor gene and bipolar affective disorder. Lancet. 346: 969. PMID 7564754 DOI: 10.1016/S0140-6736(95)91590-7 |
0.401 |
|
| 1995 |
Shaikh S, Collier D, Arranz M, Crocq M, Gill M, Kerwin R. Examination of the DRD2 (SER-CYS) variant in schizophrenia Schizophrenia Research. 15: 48. DOI: 10.1016/0920-9964(95)95156-4 |
0.58 |
|
| 1994 |
Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet. 343: 1045-6. PMID 7909081 |
0.36 |
|
| Show low-probability matches. |